Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer.
PierFranco ConteAndreas SchneeweissSibylle LoiblEleftherios P MamounasGunter von MinckwitzMax S ManoMichael UntchChiun-Sheng HuangNorman WolmarkPriya RastogiVeronique D'HondtAndrés RedondoLjiljana StamatovicHervé BonnefoiHugo Castro-SalgueroHans H FischerTanya WahlChunyan SongThomas BouletPeter TraskCharles E GeyerPublished in: Cancer (2020)
These data suggest that health-related quality of life was generally maintained in both study arms over the course of treatment.
Keyphrases
- big data
- epidermal growth factor receptor
- positive breast cancer
- patient reported outcomes
- artificial intelligence
- tyrosine kinase
- advanced non small cell lung cancer
- endothelial cells
- rectal cancer
- metastatic breast cancer
- lymph node
- open label
- locally advanced
- randomized controlled trial
- induced pluripotent stem cells
- clinical trial
- pluripotent stem cells
- combination therapy
- squamous cell carcinoma
- electronic health record
- data analysis